Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This study is a randomized Phase 3, double-blind study of maintenance pemetrexed plus best
supportive care versus placebo plus best supportive care in NSCLC. Participants must have
received 1 of 6 induction regimens for 4 cycles and did not have progressive disease prior to
randomization (enrollment) into this trial.